|
Phase I study of regorafenib in combination with vincristine and irinotecan in pediatric patients with recurrent or refractory solid tumors. |
|
|
Consulting or Advisory Role - Bayer; Halozyme; Lilly; Merck; Roche; Tesaro |
Travel, Accommodations, Expenses - Bayer; Roche |
|
|
Honoraria - Amgen; Jazz Pharmaceuticals; Roche |
Consulting or Advisory Role - Amgen; Bayer; EUSA Pharma; Sanofi |
Travel, Accommodations, Expenses - EUSA Pharma; Jazz Pharmaceuticals; Takeda |
|
|
Research Funding - Eisai Europe (Inst) |
Travel, Accommodations, Expenses - Eisai |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bayer; Tesaro |
Consulting or Advisory Role - Bayer; Tesaro |
Travel, Accommodations, Expenses - Bayer; Tesaro |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer; EUSA Pharma |
Speakers' Bureau - EUSA PHarma |
Research Funding - EUSA Pharma (Inst) |
Travel, Accommodations, Expenses - EUSA PHARMA |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Bayer |
|
|
|
Consulting or Advisory Role - Bayer |
|
|
No Relationships to Disclose |
|
|
|
|
|
Consulting or Advisory Role - AZD; Bayer; Boehringer Ingelheim; Merck KGaA (Inst); Roche/Genentech |